The Pediatric Cancer Program performs basic, translational, and clinical research with the goal of improving diagnostic, prognostic, and therapeutic approaches for childhood cancer. The Pediatric Program is a component of Texas Children?s Cancer Center (TCCC), a joint center of BCM and Texas Children?s Hospital (TCH) and is one of the country?s largest pediatric cancer programs. The Center sees approximately 600 new pediatric cancer patients each year. Its main laboratory research facilities are located at TCH. The Pediatric Program includes 28 Research and 17 Clinical Members from a number of Departments including Pediatrics, Surgery, Neurosurgery, Pathology, Medicine and Psychology. The Program?s scientific aims include, 1) to increase our biological understanding of pediatric malignancies through comprehensive molecular, genomic and proteomic analysis of these diseases, 2) to use the information from these studies to improve diagnostic, prognostic, and therapeutic approaches for pediatric cancers, 3) to identify novel molecular targets that may be exploited therapeutically, 4) to study the genetic pre-disposition for selected pediatric cancers and determine the appropriate surveillance regimens for these at-risk children, 5) to identify effective new therapies for childhood malignancies and develop and conduct innovative Phase I and Phase II trials, 6) to study the late effects of childhood cancer therapy and improve the outcomes of survivors, 7) to mentor and train pediatric oncology fellows and post-fellowship research trainees to develop the next generation of leaders and 8) to impact pediatric cancer in our catchment area, nationally and internationally. As of September 1, 2014, the Pediatric Program had $5,764,212 in active NCI grants, $4,939,272 in Total Other NIH funding, $5,261,666 in other Peer Reviewed Funding, $3,344,907 in Non-Peer Reviewed Funding, for Total Funding of $19,310,057. In the last 5 years members of the Program published 404 cancer related manuscripts in peer-reviewed journals of which 33% represented intra-programmatic collaborations, 25% inter-programmatic and 58% inter- institutional. The Program?s research accomplishments have occurred in six thematic areas organized into formal research programs including: Biologic and Therapeutic Studies of Pediatric Solid Tumors, Pediatric Neuro-oncology Research, Pediatric Cancer Genetics and Genomics, Pediatric Cancer Developmental Therapeutics, Leukemia and Lymphoma, and Cancer Survivorship. These programs facilitate and organize thematic research activities, are trans-disciplinary and involve both laboratory and clinical researchers. Programs meet regularly to discuss research collaborations and research strategy including moving projects along the translational continuum from basic research to clinical studies. The Program has 116 cancer related protocols; 64 are clinical trials, 8 developed by Program investigators. The Program has robust educational and training components including the largest accredited pediatric hematology-oncology fellowship program and three NIH training grants.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA125123-13
Application #
9759817
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2019-07-01
Budget End
2020-06-30
Support Year
13
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Baylor College of Medicine
Department
Type
DUNS #
051113330
City
Houston
State
TX
Country
United States
Zip Code
77030
Kundu, Samrat T; Grzeskowiak, Caitlin L; Fradette, Jared J et al. (2018) TMEM106B drives lung cancer metastasis by inducing TFEB-dependent lysosome synthesis and secretion of cathepsins. Nat Commun 9:2731
Kim, Myunghoo; Galan, Carolina; Hill, Andrea A et al. (2018) Critical Role for the Microbiota in CX3CR1+ Intestinal Mononuclear Phagocyte Regulation of Intestinal T Cell Responses. Immunity 49:151-163.e5
Mamonkin, Maksim; Mukherjee, Malini; Srinivasan, Madhuwanti et al. (2018) Reversible Transgene Expression Reduces Fratricide and Permits 4-1BB Costimulation of CAR T Cells Directed to T-cell Malignancies. Cancer Immunol Res 6:47-58
Morriss, Ginny R; Rajapakshe, Kimal; Huang, Shixia et al. (2018) Mechanisms of skeletal muscle wasting in a mouse model for myotonic dystrophy type 1. Hum Mol Genet 27:2789-2804
Lanza, Denise G; Gaspero, Angelina; Lorenzo, Isabel et al. (2018) Comparative analysis of single-stranded DNA donors to generate conditional null mouse alleles. BMC Biol 16:69
Jeong, Mira; Park, Hyun Jung; Celik, Hamza et al. (2018) Loss of Dnmt3a Immortalizes Hematopoietic Stem Cells In Vivo. Cell Rep 23:1-10
Boudreaux, Seth P; Duren, Ryan P; Call, Steven G et al. (2018) Drug targeting of NR4A nuclear receptors for treatment of acute myeloid leukemia. Leukemia :
Sukumaran, Sujita; Watanabe, Norihiro; Bajgain, Pradip et al. (2018) Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment. Cancer Discov 8:972-987
Kaochar, Salma; Mitsiades, Nicholas (2018) A Novel Mechanism to Drive Castration-Resistant Prostate Cancer. Trends Endocrinol Metab 29:366-368
Johnston, A N; Bu, W; Hein, S et al. (2018) Hyperprolactinemia-inducing antipsychotics increase breast cancer risk by activating JAK-STAT5 in precancerous lesions. Breast Cancer Res 20:42

Showing the most recent 10 out of 991 publications